|

|
- The pharmacological
and
microbiological basis of PK/PD : why did we need to invent PK/PD in the
first place ?
WEB
- PDF
Paul M. Tulkens (Cellular and Molecula Pharmacology, Catholic
University of Louvain, Brussels, Belgium)
- Clinical
implication 1: dose adjustments and ensuring efficacy in urinary tract
infections
WEB
- PDF
Kurt Naber (Department
of
Urology, Hospital St. Elisabeth, Straubing, Germany.
- Clinical
implication 2: dose adjustments and fighting the emergence of
resistance in pneumococci
WEB
- PDF
Donald E. Low (Department of Microbiology, Mount Sinai Hospital,
Toronto, Canada)
- Clinical
implication 3: Can and when should beta-lactams be given by continuous
infusion ?
John Turnidge (Department of Microbiology and Infectious Diseases,
Women's and Children's Hospital,
North Adelaide, Australia.)
WEB - PDF
- Clinical
implication 4: PK/PD as new approach in
the treatment of Malaria : the Philippine experience.
Dorina
Bustos (Research
Institute for Tropical Medicine, Department of Health, Alabang,
Muntinlupa City, Philippines
WEB
- PDF
|